Aacrjournals.org

Site's Categories

Category
Health Conditions and Concerns 90%
Health 5%
Medicine 5%


Explore sites in same category:
  1. foot-pain-explored.com
  2. Rank 1.8M. Estimated value 1,212$
  3. backpain-breakthrough.com
  4. Rank 143.7K. Estimated value 15,204$
  5. nfid.org
  6. Rank 424.1K. Estimated value 5,112$
  7. seikatsusyukanbyo.com
  8. Rank 471K. Estimated value 4,596$
  9. mahak-charity.org
  10. Rank 62.6K. Estimated value 35,160$
  11. preventblindness.org
  12. Rank 393.8K. Estimated value 5,508$
  13. onclive.com
  14. Rank 160.4K. Estimated value 13,620$
  15. shepherd.org
  16. Rank 693.9K. Estimated value 3,108$
  17. aafa.org
  18. Rank 163K. Estimated value 13,392$
  19. procure.ca
  20. Rank 880.3K. Estimated value 2,448$

Domain Informations

Aacrjournals.org lookup results from whois.tucows.com server:
  • Domain created: 2000-06-02T02:46:09Z
  • Domain updated: 2020-05-04T03:51:47Z
  • Domain expires: 2021-06-02T02:46:09Z 0 Years, 50 Days left
  • Website age: 20 Years, 314 Days
  • Registrar Domain ID: D28350291-LROR
  • Registrar Url: http://www.tucows.com
  • Registrar WHOIS Server: whois.tucows.com
  • Registrar Abuse Contact Email: [email protected]
  • Registrar Abuse Contact Phone: +1.4165350123
  • Name server:
    • CARL.NS.CLOUDFLARE.COM
    • YOLANDA.NS.CLOUDFLARE.COM

Network
  • inetnum : 104.16.0.0 - 104.31.255.255
  • name : CLOUDFLARENET
  • handle : NET-104-16-0-0-1
  • status : Direct Assignment
  • created : 2010-07-09
  • changed : 2021-01-11
  • desc : All Cloudflare abuse reporting can be done via https://www.cloudflare.com/abuse
Owner
  • organization : Cloudflare, Inc.
  • handle : CLOUD14
  • address : Array,San Francisco,CA,94107,US
Abuse
Technical support
Domain Provider Number Of Domains
godaddy.com 70613
namecheap.com 23889
networksolutions.com 21890
tucows.com 12872
publicdomainregistry.com 8716
whois.godaddy.com 6491
cscdbs.com 5638
enomdomains.com 5390
gmo.jp 5306
net.cn 5057

Host Informations

  • Host name: 104.16.212.26
  • IP address: 104.16.212.26
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

SEO Informations


SITE ESTIMATED VALUE : 53,700$
  • -3908 rank in 90 days
  • Reach Rank: 37,254
  • Reach Rank: 37,254
  • Global Rank: 41,109
  • United States Rank: 19,305
  • Category Rank: 60
  • Daily Visits: 32.4K visitors
  • Monthly Visits: 1M visitors

Global Rank

Traffic Trend

Site's Top Keywords

    cancer

    publications

    research

    journals

    prevention

    molecular

    ccr

    impact factor

    focus

    clinical

Email address with aacrjournals.org

Found 0 emails of this domain


DNS Records / DNS Lookup

Type TTL Extra
A 299 IP : 104.16.212.26
A 299 IP : 104.16.215.26
A 299 IP : 104.16.214.26
A 299 IP : 104.16.213.26
A 299 IP : 104.16.211.26

Check all domain's dns records

Port Checking ...

See Web Sites Hosted on 104.16.212.26

Fetching Web Sites Hosted

Keyword Suggestion

Aacr journals
Aacr journals.org
Aacr journals impact
Aacr journals impact factor
Aacr journals impact factor 2018
Aac journals
Aacr journal prices

Site Inspections

Websites Listing

Surface proteomics reveals CD72 as a target for in vitro ...

Cancerdiscovery.aacrjournals.org Mar 16, 2021  · Alternate strategies are needed for B-cell malignancy patients relapsing after CD19-targeted immunotherapy. Here, cell surface proteomics revealed CD72 as an optimal target for poor-prognosis KMT2A/MLL1-rearranged (MLLr) B-ALL, which we further found to be expressed in other B-cell malignancies. Using a recently-described, fully-in vitro system we selected synthetic CD72-specific …

Intrinsic immunogenicity of small cell lung carcinoma ...

Cancerdiscovery.aacrjournals.org Mar 11, 2021  · Small cell lung carcinoma (SCLC) is highly mutated, yet durable response to immune checkpoint blockade (ICB) is rare. SCLC also exhibits cellular plasticity, which could influence its immunobiology. Here we discover that a distinct subset of SCLC uniquely upregulates MHC I, enriching for durable ICB benefit. In vitro modeling confirms epigenetic recovery of MHC I in SCLC following …

Understanding Academic Medical Centers: Simone’s Maxims ...

Clincancerres.aacrjournals.org Academic medical centers today represent a unique fusion of traditional academia, hospital functions, several levels of education, and, above all, patients. They are complex organizations trying to discharge an often conflicting melange of responsibilities. This complexity has grown in recent years

FDA Approval Summary: Pembrolizumab plus Lenvatinib for ...

Clincancerres.aacrjournals.org On September 17, 2019, FDA granted accelerated approval to pembrolizumab plus lenvatinib for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) and who have disease progression following prior systemic therapy but are not candidates for curative surgery or radiation.

GALAD Score for Hepatocellular Carcinoma Detection in ...

Cebp.aacrjournals.org Background: The GALAD score is a serum biomarker–based model that predicts the probability of having hepatocellular carcinoma (HCC) in patients with chronic liver disease. We aimed to assess the performance of the GALAD score in comparison with liver ultrasound for detection of HCC. Methods: A single-center cohort of 111 HCC patients and 180 controls with cirrhosis or chronic hepatitis B and ...

Anti-CLL1 chimeric antigen receptor T cell therapy in ...

Clincancerres.aacrjournals.org Apr 07, 2021  · Purpose: The survival rate of children with refractory/relapsed acute myeloid leukemia (R/R-AML) by salvage chemotherapy is minimal. Treatment with chimeric antigen receptor T cells (CAR-T) has emerged as a novel therapy to improve malignancies treatment. C-type lectin-like molecule 1 (CLL1) is highly expressed on AML leukemia stem cells, blast cells, and monocytes, but not on normal ...

Combination therapies for Precision Oncology: The Ultimate ...

Clincancerres.aacrjournals.org Mar 11, 2021  · The single agent activity of MEK inhibitors in MAP kinase or CDK4/6 inhibitors in cyclin pathway aberrant tumors has been limited. The combination of trametinib and palbociclib demonstrates safety, tolerability, and clinical activity in a histology independent manner, representing a therapeutic approach for patients harboring cooccurring aberrations.

Domains Expiration Date Updated

Site Provider Expiration Date
aacrjournals.org tucows.com 50 Days
awmf.org registrar.ionos.info 237 Days
innomd.org whois.pir.org 6 Days
moonsrarebooks.com register.com 109 Days
dpelota.com godaddy.com 168 Days
rogaine.com key-systems.net 1 Year, 18 Days
montefioredental.com godaddy.com 328 Days
florastor.com nameshield.net 359 Days
montauksoundview.com godaddy.com 176 Days
uwowocosplay.com tucows.com 27 Days

    Browser All

    .com130.7K domains   

    .org33.3K domains   

    .net23.6K domains   

    .au421 domains   

    .ca5.1K domains   

    .edu2.8K domains   

    .eu2.7K domains   

    .us1.7K domains   

    .info4K domains   

    .ru21.7K domains   

    .gov1.7K domains   

    .pro1.1K domains   

    .club1.1K domains   

    .tk48 domains   

    Browser All